X0306 4 2015-02-17 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001277495 BOESS CARSTEN 33 HAYDEN AVE LEXINGTON MA 02421 false true false false SVP, Chief Financial Officer Common Stock 2015-02-17 4 M false 13235 1.7 A 13235 D Common Stock 2015-02-17 4 M false 29062 40.74 A 42297 D Common Stock 2015-02-17 4 S false 8989 98.85 D 33308 D Common Stock 2015-02-17 4 S false 14750 99.97 D 18558 D Common Stock 2015-02-17 4 S false 16716 100.74 D 1842 D Common Stock 2015-02-17 4 S false 1842 101.69 D 0 D Stock Option (Right to Buy) 1.7 2015-02-17 4 M false 13235 0 D 2021-05-25 Common Stock 13235 9929 D Stock Option (Right to Buy) 40.74 2015-02-17 4 M false 29062 0 D 2022-06-27 Common Stock 29062 15938 D The stock option exercise and sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 24, 2014. The Stock Option granted the reporting person an option to purchase 158,840 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 05/16/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. The Stock Option granted the reporting person an option to purchase 45,000 shares of the Company's common stock (the "Shares"). 25% of the Shares vested and became exercisable on 06/27/ 2013 and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $98.34 to $99.32. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $99.36 to $100.35. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $100.45 to $101.37. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $101.56 to $101.97. The price reported in this row reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Carsten Boess 2015-02-19